David Kirn, 4D Molecular Therapeutics CEO (via website)

4D Mol­e­c­u­lar Ther­a­peu­tics ac­quires eye dis­ease as­set from Fortress Biotech sub­sidiary

Cal­i­for­nia-based biotech 4D Mol­e­c­u­lar Ther­a­peu­tics (4DMT) will be ac­quir­ing the rights to an as­set from a com­pa­ny un­der the Fortress Biotech um­brel­la.

On Mon­day, 4DMT …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.